Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRISTAR: Tofogliflozin vs increased loop diuretics in diabetic heart failure with renal congestion
jRCTs051240219Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tofogliflozin in type 2 diabetes mellitus (T2DM), heart failure (HF) and renal congestion (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Change in body weight from baseline to week 6. Started Jan 2025; status: recruiting.
02
Drugs
tofogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)renal congestion
Beyond the preview
Go deeper on jRCTs051240219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240219.